Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):451-461. doi: 10.1016/j.ijrobp.2018.05.062. Epub 2018 Jun 2.
PURPOSE: To investigate hepatocellular carcinoma tumor dose-response characteristics based on voxel-level absorbed doses (D) and biological effective doses (BED) using quantitative Y-single-photon emission computed tomography (SPECT)/computed tomography (CT) after Y-radioembilization with glass microspheres. We also investigated the relationship between normal liver D and toxicities. METHODS AND MATERIALS: Y-radioembolization activity distributions for 34 patients were based on quantitative Y-bremsstrahlung SPECT/CT. D maps were generated using a local-deposition algorithm. Contrast-enhanced CT or magnetic resonance imaging scans of the liver were registered to Y-SPECT/CT, and all tumors larger than 2.5 cm diameter (53 tumors) were segmented. Tumor mean D and BED (Dmean and BEDmean) and dose volume coverage from 0% to 100% in 10% steps (D0-D100 and BED0-BED100) were extracted. Tumor response was evaluated on follow-up using World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), and modified RECIST (mRECIST) criteria. Differences in dose metrics for responders and nonresponders were assessed using the Mann-Whitney U test. A univariate logistic regression model was used to determine tumor dose metrics that correlated with tumor response. Correlations among tumor size, tumor Dmean, and tumor dose heterogeneity (defined as the coefficient of variation) were assessed. RESULTS: The objective response rates were 14 of 53, 15 of 53, and 30 of 53 for WHO, RECIST, and mRECIST criteria, respectively. WHO and RECIST response statuses did not correlate with D or BED. For mRECIST responders and nonresponders, D and BED were significantly different for Dmean, D20 to D80, BEDmean, and BED0 to BED80. Threshold doses (and the 95% confidence interval) for 50% probability of mRECIST response (D) were 160 Gy (123-196 Gy) for Dmean and 214 Gy (146-280 Gy) for BEDmean. Tumor dose heterogeneity significantly correlated with tumor volume. No statistically significant association between Dmean to normal liver and complications related to bilirubin, albumin, or ascites was observed. CONCLUSIONS: Hepatocellular carcinoma tumor dose-response curves after Y-radioembolization with glass microspheres showed Dmean of 160 Gy and BEDmean of 214 Gy for D with a positive predictive value of ∼70% and a negative predictive value of ∼62%. No complications were observed in our patient cohort for normal liver Dmean less than 44 Gy.
目的:利用 Y 放射性微球放射性栓塞后定量 Y 单光子发射计算机断层扫描(SPECT)/计算机断层扫描(CT),基于体素水平吸收剂量(D)和生物有效剂量(BED),研究肝细胞癌肿瘤剂量反应特征。我们还研究了正常肝 D 与毒性之间的关系。
方法与材料:34 例患者的 Y 放射性栓塞活性分布基于定量 Y 韧致辐射 SPECT/CT。使用局部沉积算法生成 D 图。将肝脏的增强 CT 或磁共振成像扫描与 Y-SPECT/CT 配准,并对所有大于 2.5cm 直径的肿瘤(53 个肿瘤)进行分割。提取肿瘤平均 D 和 BED(Dmean 和 BEDmean)以及 0%至 100%的 10%步长的剂量体积覆盖率(D0-D100 和 BED0-BED100)。使用世界卫生组织(WHO)、实体瘤反应评估标准(RECIST)和改良 RECIST(mRECIST)标准对随访时的肿瘤反应进行评估。使用 Mann-Whitney U 检验评估应答者和无应答者之间的剂量指标差异。使用单变量逻辑回归模型确定与肿瘤反应相关的肿瘤剂量指标。评估肿瘤大小、肿瘤 Dmean 和肿瘤剂量异质性(定义为变异系数)之间的相关性。
结果:根据 WHO、RECIST 和 mRECIST 标准,客观缓解率分别为 53 例中的 14 例、15 例和 30 例。WHO 和 RECIST 反应状态与 D 或 BED 不相关。对于 mRECIST 应答者和无应答者,Dmean、D20 至 D80、BEDmean 和 BED0 至 BED80 的 D 和 BED 差异有统计学意义。mRECIST 反应概率为 50%(D)的阈值剂量(95%置信区间)分别为 Dmean 为 160Gy(123-196Gy)和 BEDmean 为 214Gy(146-280Gy)。肿瘤剂量异质性与肿瘤体积显著相关。未观察到 Dmean 与胆红素、白蛋白或腹水相关并发症之间存在统计学显著关联。
结论:Y 放射性微球放射性栓塞后肝细胞癌肿瘤剂量反应曲线显示,Dmean 为 160Gy,BEDmean 为 214Gy,D 的阳性预测值约为 70%,阴性预测值约为 62%。我们的患者队列中,正常肝 Dmean 小于 44Gy 时未观察到并发症。
Int J Radiat Oncol Biol Phys. 2018-6-2
Eur J Nucl Med Mol Imaging. 2020-12
Eur J Nucl Med Mol Imaging. 2025-5-22
Front Immunol. 2025-4-16
Eur J Nucl Med Mol Imaging. 2024-3
J Appl Clin Med Phys. 2024-2